{
    "root": "c11ff279-c752-44b6-bf85-a7c86670fd4c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mirtazapine",
    "value": "20240716",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MIRTAZAPINE",
            "code": "A051Q2099Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6950"
        }
    ],
    "indications": {
        "text": "mirtazapine tablets indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 starting dose : 15-mg daily ; may increase maximum recommended dose 45 mg daily . ( 2.1 ) \u2022 administer orally daily , preferably evening prior sleep . ( 2.1 ) \u2022 reduce dose gradually discontinuing mirtazapine tablets . ( 2.6 , 5.14 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "mirtazapine tablets , usp supplied : 30 mg - reddish-brown , oval , biconvex tablet - film coated tablets \u201c 500 \u201d debossed one side scored side . ndc 72162-1640-02 bottle 45 tablets ndc 72162-1640-03 bottle 30 tablets ndc 72162-1640-05 bottle 500 tablets ndc 72162-1640-00 bottle 1000 tablets storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) . [ usp controlled room temperature ] . protect light moisture . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "mirtazapine tablets contraindicated patients : \u2022taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . \u2022with known hypersensitivity mirtazapine excipients mirtazapine tablets . severe skin , including reaction eosinophilia systemic symptoms ( dress ) , stevens-johnson syndrome , bullous dermatitis , erythema multiforme toxic epidermal necrolysis reported following mirtazapine tablets [ ( 5.6 ) , ( 6.2 ) ] .",
    "indications_original": "Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults \n                        [see Clinical Studies (14)].",
    "contraindications_original": "\u2022 Starting dose: 15-mg once daily; may increase up to maximum recommended dose of 45 mg once daily. (2.1) \u2022 Administer orally once daily, preferably in the evening prior to sleep. (2.1) \u2022 Reduce dose gradually when discontinuing mirtazapine tablets. ( 2.6 , 5.14 )",
    "warningsAndPrecautions_original": "Mirtazapine tablets, USP are supplied as:\n                  30 mg -\u00a0Reddish-brown, oval, biconvex tablet -\u00a0film coated tablets with \u201c500\u201d debossed on one side and scored on the other side.\n                  NDC 72162-1640-02 Bottle of 45 tablets\n                  NDC 72162-1640-03 Bottle of 30 tablets\n                  NDC 72162-1640-05 Bottle of 500 tablets\u00a0\n                  NDC 72162-1640-00 Bottle of 1000 tablets\n                  \n                     \n                        Storage\n                     \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). [see USP Controlled Room Temperature]. Protect from light and moisture.\n                  Repackaged/Relabeled by:\n                  Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Mirtazapine tablets are contraindicated in patients: \n                  \n                     \n                        \u2022Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome \n                           [see Warnings and Precautions (5.3), Drug Interactions (7)].\n                        \n                     \n                     \n                        \u2022With a known hypersensitivity to mirtazapine or to any of the excipients in mirtazapine tablets. Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have been reported following the use of mirtazapine tablets \n                           [see Warnings and Precautions (5.6), Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Mirtazapine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6950"
        }
    ]
}